Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, Ecolab (ECL - Analyst Report) launched its latest range of USDA BioPreferred and Green Seal certified bio-based hard surface cleaners. The new product line includes a peroxide multi-surface cleaner, glass cleaner, acid bathroom cleaner and neutral bathroom cleaner.
These offerings will enhance the portfolio of Ecolab’s US Cleaning and Sanitizing segment. Revenues for the segment increased 1% year over year (5% on a pro forma basis) to $760.9 million in the second quarter of 2012. Institutional sales increased 3% year over year on the back of market share gains in the last quarter.
Ecolab witnessed steadfast growth in demand for its products from lodging facilities in the second quarter. As the company’s latest organic solutions are designed for lodging, commercial and facility operations, the new product launches should drive segment sales. Marketing initiatives and better field technology are expected to bolster sales of its latest range of bio-based hard surface cleaners.
St. Paul, Minnesota-based Ecolab serves the food service, food and beverage processing, healthcare, energy, water treatment and hospitality markets both in the U.S. as well as internationally. The company continues to invest in strategic areas such as health care, food, water and energy and global pest elimination to expand its business. Management’s current emphasis is on product innovation, sales organization, volume growth, appropriate pricing, and merger synergies along with the rationalization of operating costs.
With a background of robust growth, Ecolab is poised to gain momentum via its aggressive strategy of pursuing acquisitions. The company recently announced the acquisition of privately-owned Champion Technologies and its related company Corsicana Technologies for $2.2 billion, in cash and stock. Moreover, Ecolab’s growth has been buoyed by its strong international presence, especially in emerging markets like Asia-Pacific and Latin America.
Despite the impressive strong international exposure, we remain cautious on Ecolab owing to the aggressive competition from the likes of Clorox (CLX - Analyst Report) and Church & Dwight (CHD - Snapshot Report). Raw material price inflation and higher delivered product cost continue to be headwinds for the company.
We currently have a long-term ‘Neutral’ recommendation on Ecolab.
Get the full Analyst Report on ECL - FREE
Get the full Snapshot Report on CHD - FREE
Get the full Analyst Report on CLX - FREE